Treatment of colorectal peritoneal metastases with oxaliplatin induces biomarkers predicting response to immune checkpoint blockade.
Saved in:
| Title: | Treatment of colorectal peritoneal metastases with oxaliplatin induces biomarkers predicting response to immune checkpoint blockade. |
|---|---|
| Authors: | Constantinides A; Laboratory Translational Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgical Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands., Lansu N; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), and University Medical Center Utrecht, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Mosen P; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, the Netherlands., Rauwerdink P; Laboratory Translational Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgical Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgery, Antonius Hospital, Nieuwegein, the Netherlands., Strating E; Laboratory Translational Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgical Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands., Völlmy F; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, the Netherlands., Nederend M; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands., Leusen JHW; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands., Rovers K; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands., Wassenaar E; Laboratory Translational Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgical Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands., Lurvink R; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Altelaar M; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, the Netherlands., Nienhuijs S; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Wiezer R; Department of Surgery, Antonius Hospital, Nieuwegein, the Netherlands., Borel Rinkes IHM; Laboratory Translational Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgical Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands., Boerma D; Department of Surgery, Antonius Hospital, Nieuwegein, the Netherlands., Kops GJPL; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW), and University Medical Center Utrecht, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands., de Hingh I; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands; Department of Epidemiology, GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands. Electronic address: ignace.d.hingh@catharinaziekenhuis.nl., Kranenburg O; Laboratory Translational Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgical Oncology, Division Imaging and Cancer, University Medical Center Utrecht, Utrecht, the Netherlands; Utrecht Platform for Organoid Technology, Utrecht University, Utrecht, the Netherlands. Electronic address: o.kranenburg@umcutrecht.nl. |
| Source: | Translational oncology [Transl Oncol] 2025 Sep; Vol. 59, pp. 102464. Date of Electronic Publication: 2025 Jul 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1936-5233 (Print) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
